GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NightHawk Biosciences Inc (LTS:0A4E) » Definitions » EV-to-EBIT

NightHawk Biosciences (LTS:0A4E) EV-to-EBIT : -0.47 (As of Jun. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is NightHawk Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NightHawk Biosciences's Enterprise Value is $16.67 Mil. NightHawk Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-35.77 Mil. Therefore, NightHawk Biosciences's EV-to-EBIT for today is -0.47.

The historical rank and industry rank for NightHawk Biosciences's EV-to-EBIT or its related term are showing as below:

LTS:0A4E' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.85   Med: -0.58   Max: 1.18
Current: -0.48

During the past 13 years, the highest EV-to-EBIT of NightHawk Biosciences was 1.18. The lowest was -9.85. And the median was -0.58.

LTS:0A4E's EV-to-EBIT is ranked worse than
100% of 437 companies
in the Biotechnology industry
Industry Median: 8.79 vs LTS:0A4E: -0.48

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NightHawk Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil. NightHawk Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-35.77 Mil. NightHawk Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.


NightHawk Biosciences EV-to-EBIT Historical Data

The historical data trend for NightHawk Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NightHawk Biosciences EV-to-EBIT Chart

NightHawk Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.14 -0.42 0.56 0.25 -0.48

NightHawk Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.16 -0.34 -0.48 -0.46

Competitive Comparison of NightHawk Biosciences's EV-to-EBIT

For the Biotechnology subindustry, NightHawk Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NightHawk Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NightHawk Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NightHawk Biosciences's EV-to-EBIT falls into.



NightHawk Biosciences EV-to-EBIT Calculation

NightHawk Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=16.670/-35.77
=-0.47

NightHawk Biosciences's current Enterprise Value is $16.67 Mil.
NightHawk Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NightHawk Biosciences  (LTS:0A4E) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NightHawk Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-35.77/0
= %

NightHawk Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil.
NightHawk Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NightHawk Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NightHawk Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


NightHawk Biosciences (LTS:0A4E) Business Description

Traded in Other Exchanges
Address
627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560
NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.

NightHawk Biosciences (LTS:0A4E) Headlines

No Headlines